Clinical trials (CTs) play a crucial role in advancing new oncology therapies and their eventual integration into cancer care. However, despite the increasing number of available CTs, <5% of patients with cancer are included.1 The biggest challenge in getting patients with cancer to participate in CTs is the lack of available trials at the hospital where the patient is being treated, due to the heterogeneous distribution of CTs.2 Other key factors that significantly influence patient recruitment for CTs and still require substantial attention are significant social disparities and certain structural issues within health care systems, such as incompatibilities between public and private systems within the same country.